Spark Therapeutics Inc., of Philadelphia, said for the year ended Dec. 31, it recognized $64.7 million in total revenue, of which $27 million was due to net product sales of Luxturna (voretigene neparvovec-rzyl), its gene therapy for treating retinal dystrophy arising from biallelic RPE65 mutations, and $37.8 million as earned in contract revenue.